CoChat

Gestational Diabetes: Risk or Myth?

Buchanan, Thomas A., Kjos, Siri L. · 1999 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

There is a wide spectrum of views regarding the clinical significance of the entity known as gestational diabetes mellitus (GDM). At one end of the spectrum are advocates of strict evidence-based medical care who argue that there is insufficient evidence for preventable morbidity resulting from asymptomatic maternal hyperglycemia during pregnancy to warrant routine detection and treatment of GDM. At the other end are advocates of universally strict glycemic control during pregnancy. They argue that even minimal maternal hyperglycemia is potentially dangerous and worthy of detection and aggressive treatment. As is often the case when such wide ranging views abound, truth and prudence seem to lie somewhere between the extremes. There is evidence that asymptomatic hyperglycemia during pregnancy is attended by important morbidity in the mother and offspring; at least some of the morbidity can be reduced by detection and treatment of GDM. However, over the range of glycemia generally encountered in GDM, only a subset of women and their infants are at risk for morbidity related to maternal hyperglycemia. Ignoring all asymptomatic hyperglycemia during pregnancy will result in inattention to important morbidities in the population. Aggressive detection and treatment of even minimal hyperglycemia during pregnancy will lead to unnecessary overtreatment of many women. The logical solution to this dilemma is the development of methods to stratify patients with GDM, regarding perinatal and long-term health risks, so that treatments can be tested and applied in the highest risk cases. The emphasis of this commentary will be on measures that can be taken in that regard. There is quite firm evidence that increasing maternal glycemia during pregnancy is associated with an increasing risk of clinically important morbidity in infants. The most obvious evidence comes from women with established diabetes, whose infants suffer an increased risk of congenital anomalies, in proportion to maternal glycemia, during the first trimester and an increased risk of several perinatal complications, in proportion to maternal glycemia, during later pregnancy. These problems are not limited to women with diagnosed diabetes. At least one cross-sectional study of women with hyperglycemia first detected during pregnancy revealed that presentation with a fasting serum glucose more than 120 mg/dL was associated with a doubling of the risk of congenital anomalies in newborns (1). Blinded (2) and unblinded (3) evaluations of maternal glucose levels during the latter half of pregnancy have revealed a fairly slow and continuous increase in complications, like macrosomia and cesarean delivery, as maternal glucose levels rise in the subdiabetic range. These findings indicate that rising maternal glycemia should be viewed as a risk factor for adverse perinatal outcomes. There may be a glucose threshold above which the risk of congenital anomalies increases sharply in early pregnancy, but there does not seem to be any such threshold for complications related to excess fetal nutrition and overgrowth in later pregnancy. Thus, maternal glycemia cannot be used to discriminate clearly between low and high risks for late-pregnancy complications, which are the major concern in GDM. The continuous relation between maternal glycemia and macrosomia-related perinatal risks accounts for much of the controversy in the diagnosis and management of GDM. Without a biological threshold for risk, there can be no proof of a superior set of diagnostic criteria or therapeutic guidelines based on maternal glucose alone. One of three general approaches can be taken: 1) set a low and very sensitive glucose threshold for identifying at-risk pregnancies and treat all patients who exceed that threshold; 2) set a very high and insensitive threshold and treat only patients who exceed it; or 3) set a low glucose threshold and, among women who exceed it, use additional information to identify patients at high or low risk when making decisions about monitoring and treatment. The first approach has been taken by advocates of universally strict glycemic control during pregnancy. They have shown that it is possible to eliminate the 10–20% excess risk of complications such as fetal macrosomia in women with diagnosed GDM, by having all patients perform capillary glucose monitoring and by administering insulin to the 50–70% of patients whose glucose exceeds very strict postprandial glucose thresholds. The fraction of women treated with this approach is generally quite high, compared with the fraction of pregnancies in which morbidity is prevented. Nonetheless, this approach has been reported to be cost effective in one retrospective analysis (4). The cost effectiveness of this approach may decrease as glucose thresholds for diagnosing GDM are lowered (5), resulting in more low-risk women being given the diagnosis. The second approach, of setting a high threshold for abnormality, is essentially

Overview

Integrity signals

Registry

Crossref · 10.1210/jcem.84.6.5714

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 13 references

Cited by

See all 26

Metadata

Authors
Buchanan, T. A., & Kjos, S. L.
Affiliations
University of Southern California (US)
Corresponding author
Buchanan, Thomas A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1999-06
Volume
84
Issue
6
Pages
1854-1857
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4254685230
Cited by
23
References
11
Citations by year
2012: 4
FWCI
2.19
Type
journal article
Language
en
Open access
closed
Locations
The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
gestational diabetes mellitus, maternal hyperglycemia, glycemic control, risk stratification, congenital malformations, perinatal complications, macrosomia, cesarean section, overtreatment, glycemic thresholds, fetal hypoglycemia, fetal growth restriction, fetal hypoxia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gestational Diabetes: Risk or Myth? https://app.cochat.ai/papers/10.1210/jc.84.6.1854
The paper
Buchanan, T. A., & Kjos, S. L. (1999). Gestational Diabetes: Risk or Myth? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.6.1854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.